Drug intelligence / Profile preview

paracetamol + phenylephrine + pheniramine + ascorbic acid (Astrapharm)

Development stage
Unknown
Lead developer
Astrapharm
Modality
Small Molecules
Administration
Oral
01

Overview

Astracitron Extra is a multi-component pharmaceutical product developed by Astrapharm for the symptomatic treatment of acute respiratory viral infections and influenza. Formulated as a powder for oral solution in sachets, it contains a combination of four active ingredients: paracetamol, phenylephrine hydrochloride, pheniramine maleate, and ascorbic acid (Vitamin C). Paracetamol serves as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system. Phenylephrine hydrochloride is a sympathomimetic decongestant that acts on alpha-1 adrenergic receptors to reduce swelling of the nasal mucosa. Pheniramine maleate is an antihistamine that blocks H1 receptors, thereby reducing allergic-like symptoms such as rhinorrhea and lacrimation. Ascorbic acid is included to support the immune system and compensate for the increased demand for Vitamin C during infection. The "Extra" formulation is specifically characterized by a higher dose of paracetamol (650 mg) compared to the standard version, providing enhanced relief for fever and severe pain.

Brand names
Astracitron Extra
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)TRPA1 (Transient receptor potential cation channel subfamily A member 1)M1 (Muscarinic acetylcholine receptor M1)HRH1 (Histamine H1 Receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ADRA1A (α1A)ADRA2A (α2A)

Beyond the preview

Go deeper on paracetamol + phenylephrine + pheniramine + ascorbic acid (Astrapharm).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paracetamol + phenylephrine + pheniramine + ascorbic acid (Astrapharm).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call